Literature DB >> 28973084

Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.

Stefan P Brugger1,2,3, Oliver D Howes2,3,4.   

Abstract

Importance: Schizophrenia is associated with alterations in mean regional brain volumes. However, it is not known whether the clinical heterogeneity seen in the disorder is reflected at the neurobiological level, for example, in differences in the interindividual variability of these brain volumes relative to control individuals. Objective: To investigate whether patients with first-episode schizophrenia exhibit greater variability of regional brain volumes in addition to mean volume differences. Data Sources: Studies that reported regional brain volumetric measures in patients and controls by using magnetic resonance imaging in the MEDLINE, EMBASE, and PsycINFO databases from inception to October 1, 2016, were examined. Study Selection: Case-control studies that reported regional brain volumes in patients with first-episode schizophrenia and healthy controls by using magnetic resonance imaging were selected. Data Extraction and Synthesis: Means and variances (SDs) were extracted for each measure to calculate effect sizes, which were combined using multivariate meta-analysis. Main Outcomes and Measures: Relative variability of regional brain volumetric measurements in patients compared with control groups as indexed by the variability ratio (VR) and coefficient of variation ratio (CVR). Hedges g was used to quantify mean differences.
Results: A total of 108 studies that reported measurements from 3901 patients (1272 [32.6%] female) with first-episode schizophrenia and 4040 controls (1613 [39.9%] female) were included in the analyses. Variability of putamen (VR, 1.13; 95% CI, 1.03-1.24; P = .01), temporal lobe (VR, 1.12; 95% CI, 1.04-1.21; P = .004), thalamus (VR, 1.16; 95% CI, 1.07-1.26; P < .001), and third ventricle (VR, 1.43; 95% CI, 1.20-1.71; P < 1 × 10-5) volume was significantly greater in patients, whereas variability of anterior cingulate cortex volume was lower (VR, 0.89; 95% CI, 0.81-0.98; P = .02). These findings were robust to choice of outcome measure. There was no evidence of altered variability of caudate nucleus or frontal lobe volumes. Mean volumes of the lateral (g = 0.40; 95% CI, 0.29-0.51; P < .001) and third ventricles (g = 0.43; 95% CI, 0.26-0.59; P < .001) were greater, whereas mean volumes of the amygdala (g = -0.46; -0.65 to -0.26; P < .001), anterior cingulate cortex (g = -0.26; 95% CI, -0.43 to -0.10; P = .005), frontal lobe (g = -0.31; 95% CI, -0.44 to -0.19; P = .001), hippocampus (g = -0.66; 95% CI, -0.84 to -0.47; P < .001), temporal lobe (g = -0.22; 95% CI, -0.36 to -0.09; P = .001), and thalamus (g = -0.36; 95% CI, -0.57 to -0.15; P = .001) were lower in patients. There was no evidence of altered mean volume of caudate nucleus or putamen. Conclusions and Relevance: In addition to altered mean volume of many brain structures, schizophrenia is associated with significantly greater variability of temporal cortex, thalamus, putamen, and third ventricle volumes, consistent with biological heterogeneity in these regions, but lower variability of anterior cingulate cortex volume. This finding indicates greater homogeneity of anterior cingulate volume and, considered with the significantly lower mean volume of this region, suggests that this is a core region affected by the disorder.

Entities:  

Mesh:

Year:  2017        PMID: 28973084      PMCID: PMC5669456          DOI: 10.1001/jamapsychiatry.2017.2663

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  41 in total

1.  A practical introduction to multivariate meta-analysis.

Authors:  Dimitris Mavridis; Georgia Salanti
Journal:  Stat Methods Med Res       Date:  2012-01-23       Impact factor: 3.021

Review 2.  Attention should be given to multiplicity issues in systematic reviews.

Authors:  Ralf Bender; Catey Bunce; Mike Clarke; Simon Gates; Stefan Lange; Nathan L Pace; Kristian Thorlund
Journal:  J Clin Epidemiol       Date:  2008-09       Impact factor: 6.437

3.  Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

Authors:  Arsime Demjaha; Alice Egerton; Robin M Murray; Shitij Kapur; Oliver D Howes; James M Stone; Philip K McGuire
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

4.  Motion and morphometry in clinical and nonclinical populations.

Authors:  Heath R Pardoe; Rebecca Kucharsky Hiess; Ruben Kuzniecky
Journal:  Neuroimage       Date:  2016-05-03       Impact factor: 6.556

5.  Response trajectories in "real-world" naturalistically treated schizophrenia patients.

Authors:  Rebecca Schennach; Sebastian Meyer; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Hans-Jürgen Möller; Michael Riedel
Journal:  Schizophr Res       Date:  2012-06-02       Impact factor: 4.939

6.  Identification of a common neurobiological substrate for mental illness.

Authors:  Madeleine Goodkind; Simon B Eickhoff; Desmond J Oathes; Ying Jiang; Andrew Chang; Laura B Jones-Hagata; Brissa N Ortega; Yevgeniya V Zaiko; Erika L Roach; Mayuresh S Korgaonkar; Stuart M Grieve; Isaac Galatzer-Levy; Peter T Fox; Amit Etkin
Journal:  JAMA Psychiatry       Date:  2015-04       Impact factor: 21.596

7.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

8.  Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study.

Authors:  J Mourao-Miranda; A A T S Reinders; V Rocha-Rego; J Lappin; J Rondina; C Morgan; K D Morgan; P Fearon; P B Jones; G A Doody; R M Murray; S Kapur; P Dazzan
Journal:  Psychol Med       Date:  2011-11-07       Impact factor: 7.723

9.  A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Br J Psychiatry       Date:  2014-07       Impact factor: 9.319

10.  The hubs of the human connectome are generally implicated in the anatomy of brain disorders.

Authors:  Nicolas A Crossley; Andrea Mechelli; Jessica Scott; Francesco Carletti; Peter T Fox; Philip McGuire; Edward T Bullmore
Journal:  Brain       Date:  2014-06-19       Impact factor: 13.501

View more
  81 in total

1.  Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk.

Authors:  Dag Alnæs; Tobias Kaufmann; Dennis van der Meer; Aldo Córdova-Palomera; Jaroslav Rokicki; Torgeir Moberget; Francesco Bettella; Ingrid Agartz; Deanna M Barch; Alessandro Bertolino; Christine L Brandt; Simon Cervenka; Srdjan Djurovic; Nhat Trung Doan; Sarah Eisenacher; Helena Fatouros-Bergman; Lena Flyckt; Annabella Di Giorgio; Beathe Haatveit; Erik G Jönsson; Peter Kirsch; Martina J Lund; Andreas Meyer-Lindenberg; Giulio Pergola; Emanuel Schwarz; Olav B Smeland; Tiziana Quarto; Mathias Zink; Ole A Andreassen; Lars T Westlye
Journal:  JAMA Psychiatry       Date:  2019-07-01       Impact factor: 21.596

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  From nodes to networks: How methods for defining nodes influence inferences regarding network interactions.

Authors:  Dimitri Falco; Asadur Chowdury; David R Rosenberg; Vaibhav A Diwadkar; Steven L Bressler
Journal:  Hum Brain Mapp       Date:  2018-12-07       Impact factor: 5.038

4.  Connectome-Based Patterns of First-Episode Medication-Naïve Patients With Schizophrenia.

Authors:  Long-Biao Cui; Yongbin Wei; Yi-Bin Xi; Alessandra Griffa; Siemon C De Lange; René S Kahn; Hong Yin; Martijn P Van den Heuvel
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

5.  Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis.

Authors:  Stephanie Winkelbeiner; Stefan Leucht; John M Kane; Philipp Homan
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

6.  Meta-analytic evidence for altered mesolimbic responses to reward in schizophrenia.

Authors:  Henry W Chase; Polina Loriemi; Tobias Wensing; Simon B Eickhoff; Thomas Nickl-Jockschat
Journal:  Hum Brain Mapp       Date:  2018-03-24       Impact factor: 5.038

7.  We need an operational framework for heterogeneity in psychiatric research

Authors:  Abraham Nunes; Thomas Trappenberg; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2020-01-01       Impact factor: 6.186

8.  Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning.

Authors:  Ganesh B Chand; Dominic B Dwyer; Guray Erus; Aristeidis Sotiras; Erdem Varol; Dhivya Srinivasan; Jimit Doshi; Raymond Pomponio; Alessandro Pigoni; Paola Dazzan; Rene S Kahn; Hugo G Schnack; Marcus V Zanetti; Eva Meisenzahl; Geraldo F Busatto; Benedicto Crespo-Facorro; Christos Pantelis; Stephen J Wood; Chuanjun Zhuo; Russell T Shinohara; Haochang Shou; Yong Fan; Ruben C Gur; Raquel E Gur; Theodore D Satterthwaite; Nikolaos Koutsouleris; Daniel H Wolf; Christos Davatzikos
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

Review 9.  Mental disorders and an acidic glycan-from the perspective of polysialic acid (PSA/polySia) and the synthesizing enzyme, ST8SIA2.

Authors:  Chihiro Sato; Masaya Hane
Journal:  Glycoconj J       Date:  2018-07-30       Impact factor: 2.916

10.  Anterior vs Posterior Hippocampal Subfields in an Extended Psychosis Phenotype of Multidimensional Schizotypy in a Nonclinical Sample.

Authors:  Lili Sahakyan; Tina Meller; Ulrika Evermann; Simon Schmitt; Julia-Katharina Pfarr; Jens Sommer; Thomas R Kwapil; Igor Nenadić
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.